
News|Articles|June 20, 2024
Emerging Biosimilars and the Importance of Identifying Experienced Providers
Author(s)PurpleLab
Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.
Trending on Applied Clinical Trials Online
1
Lab Orchestration Is Not What You Think It Is
2
From Participation to Understanding: Reframing Engagement in Clinical Trials
3
ACT Brief: Patient Voice in Protocol Design, AI-Informed Recruitment Workflows, and Engagement Maturity Beyond Performative
4
Recruitment in the Age of AI: Q&A with John Worden, Javara
5